未登录

P

Pascal Maisonobe

University of California Los Angeles

H指数:23

被引数:2,201

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity

IV期、随机、双盲、交叉研究，比较阿波保 toxin A 和奥保 toxin A 在成人上肢痉挛中的临床安全性与有效性

Advances in Therapy

IF4

2026-05-200

OAAI

Achieving treatment goals with repeated injections of botulinum toxin in adults with leg spasticity

通过反复注射肉毒毒素实现成人腿部痉挛的治疗目标

Current Medical Research and Opinion

IF2.2

2025-12-010

PRE

MUSCLE SELECTION AND DOSING IN PATIENTS UNDERGOING TREATMENT WITH ABOBOTULINUMTOXINA FOR LOWER LIMB SPASTICITY IN REAL-WORLD PRACTICE

肌肉选择和剂量在真实世界实践中接受ABOBOULINUMTOXINA治疗下肢痉挛患者的应用

JOURNAL OF REHABILITATION MEDICINE

IF2.3

2025-02-070

OA

Botulinum Toxin Type A (BoNT-A) Use for Post-Stroke Spasticity: A Multicenter Study Using Natural Language Processing and Machine Learning

A型肉毒毒素 (bont-a) 用于中风后痉挛: 使用自然语言处理和机器学习的多中心研究

IF4

2024-08-021

OAAI

A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity

IF4

2023-08-300

OAAI

Leg Activity Measure (LegA) sensitivity to change following treatment of lower limb spasticity with a single cycle of abobotulinumtoxinA in an ambulant population

IF8.5

2023-04-250

PRE

Post Hoc Subgroup Analysis of the BCause Study Assessing the Effect of AbobotulinumtoxinA on Post-Stroke Shoulder Pain in Adults

IF4

2022-11-205

OAAI

AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol

ADVANCES IN THERAPY

IF4

2021-09-255

OAAI

The Effectiveness of Botulinum Toxin Type A (BoNT-A) Treatment in Brazilian Patients with Chronic Post-Stroke Spasticity: Results from the Observational, Multicenter, Prospective BCause Study

IF4

2020-12-0410

OAAI

Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2020-09-0110

OAAI

Effectiveness of botulinum neurotoxin type A injections in naive and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2019-04-016

OAAI

Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study

早期的AbobotulinumtoxinA (运动障碍®) 中风后成人上肢痉挛: ONTIME试点研究

IF4

2018-06-2132

OAAI

Effect of early use of abobotulinumtoxina on time to post-stroke spasticity progression: Results of the ontime pilot study

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2017-10-010

PREAI

Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial

CLINICAL THERAPEUTICS

IF3.6

2016-08-019

PREAI

Factors and Regional Differences Associated with Endometriosis: A Multi-Country, Case-Control Study

ADVANCES IN THERAPY

IF4

2016-06-2426

OAAI

Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III)

IF2.3

2016-06-1726

OAAI

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

DIGESTIVE AND LIVER DISEASE

IF3.8

2016-05-0144

OAAI

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

EUROPEAN JOURNAL OF ENDOCRINOLOGY

IF5.2

2015-09-0134

OAAI

Factors Influencing Goal Attainment in Patients with Post-Stroke Upper Limb Spasticity Following Treatment with Botulinum Toxin A in Real-Life Clinical Practice: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study

IF4

2015-04-0822

OAAI

Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia

PARKINSONISM & RELATED DISORDERS

IF3.4

2015-02-0125

PREAI